PTC857, Placebo to match PTC857 60 mg/mL oral solution, Utreloxastat 62.5
PTC857-CNS-001-ALS
Phase 2 small_molecule active
Quick answer
PTC857, Placebo to match PTC857 60 mg/mL oral solution, Utreloxastat 62.5 for Amyotrophic Lateral Sclerosis is a Phase 2 program (small_molecule) at PTC THERAPEUTICS, INC. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- PTC THERAPEUTICS, INC.
- Indication
- Amyotrophic Lateral Sclerosis
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active